First in human proof-of-concept Phase I/ II Trial in Werner Syndrome

Genflow Biosciences is rapidly establishing itself as a preeminent biotechnology firm focused on longevity. With an ambitious clinical development plan in place, our adept team of industry leaders and researchers is focused on imminent milestones. In Sardinia, we are initiating a pioneering human proof-of-concept Phase I/II trial for Werner Syndrome. Werner Syndrome serves as a model for studying premature ageing in humans. Investigating its causes offers valuable insights into the ageing process and may lead to strategies that enhance overall health and longevity.

First in human proof-of-concept Phase I/ II Trial in MASH

MASH or Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a liver disease with a significant unmet medical need. Effecting an estimated 35 million people worldwide, it is the most chronic liver condition in the West and patient numbers are growing rapidly. It is the leading cause of liver transplants due to the lack of approved therapies with the market for MASH therapy expected to reach $27.2B by 2029. Recent pre-clinical programs have highlighted the adipogenic, anti-fibrotic, and anti-tumoral effects of GF-1002 positioning it as a promising treatment candidate for MASH. By targeting MASH, Genflow Biosciences stands to benefit from a clear regulatory pathway that could lead to accelerated development and the potential for conditional fast-track approval.